🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Recurrence pattern in localized #RCC: Results from a #European multicenter database (RECUR). #BeyondTheAbstract with Giuseppe Fallara and Umberto Capitanio Ospedale San Raffaele on UroToday > bit.ly/3hakwQ5 Urologic Oncology

How to optimize the use of adjuvant pembrolizumab in #RenalCellCarcinoma: Which patients benefit the most? #BeyondTheAbstract with Giuseppe Fallara and Umberto Capitanio Ospedale San Raffaele on UroToday > bit.ly/3uD89Pv World Journal of Urology

The end of an incredibly rewarding and unforgettable journey! Thanks to everyone I encountered throughout my path! Finally Urologist! ⁦Ospedale San Raffaele⁩ #urology #urosome

How to optimize the use of adjuvant pembrolizumab in #RenalCellCarcinoma: Which patients benefit the most? #BeyondTheAbstract with Giuseppe Fallara and Umberto Capitanio Ospedale San Raffaele on UroToday > bit.ly/3uD89Pv World Journal of Urology

Infertile men are less healthy than fertile men: in this study we showed that a mild kidney function impairment can be found in up to 9% of unaware young infertile men @Edop92 Paolo Capogrosso Federico Belladelli Christian Corsini Luca Boeri M.D. onlinelibrary.wiley.com/doi/abs/10.111…

Out our latest systematic review and meta-analysis on ORC vs RARC. Not outstanding benefits for the 🤖 in terms of peri-operative outcomes but some interesting hints. Great collab with EAU Young Academics robotic working group Paolo Dell'Oglio Alessandro Larcher pubmed.ncbi.nlm.nih.gov/36999835/

The debate regarding to clamp or not to clamp during partial nephrectomy and the acceptable duration of ischaemia time is still ongoing. Check out our relevant work on this important topic! Alessandro Larcher Umberto Capitanio Giuseppe_Basile Giuseppe Fallara bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

HoLEP is challenging even for surgeon with high experience and it is not devoid of complications. Patient counselling is key. Out our prospective study Eur Urol Focus Paolo Capogrosso Eugenio Ventimiglia Daniele Cignoli Federico Belladelli Gianmarco Colandrea, MD sciencedirect.com/science/articl…

Calling all reg-level fellows! Join our teams KCH_Urology Denmark Hill or PRUH from October 2023. Adverts out: tinyurl.com/5fncmp2x tinyurl.com/25cvhmxc

The influence of age and comorbidities during decision-making for patients with renal cell carcinoma remains controversial. Check out our systematic review on this relevant topic. Giuseppe Fallara Giuseppe_Basile Alessandro Larcher Umberto Capitanio Kidney Cancer content.iospress.com/articles/kidne…

Online now: The immune-related adverse events paradox in locally advanced or metastatic #UrothelialCancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 Trials by Alberto Martini et al bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

#MedTwitter #twittorial to follow - tune in with us Daniele Robesti Giuseppe Fallara Pavlos Msaouel More to come Vivli

Current Issue: Treatment of Persistent or Recurrent Varicoceles: A Systematic Review buff.ly/46KkoM6 Giuseppe Fallara K4rL @Edop92 Federico Belladelli Paolo Capogrosso Hussain M Alnajjar Francesco Montorsi Andrea Salonia, MD. PhD Fabio Castiglione Prof Asif Muneer #UroSoMe #Medtwitter

Infertile men are at higher risk of dying and of being diagnosed with other comorbidities over time compared to fertile men: results from our latest systematic review and meta-analysis @Edop92 Paolo Capogrosso Luca Boeri M.D. Federico Belladelli Eur Urol Focus eu-focus.europeanurology.com/article/S2405-…

99mTc‐Sestamibi #PET in #RCC 🩺🛸🧲European Urology European Association of Urology (EAU) EAU Young Academics European School of Urology (EAU ESU) Università Vita-Salute San Raffaele authors.elsevier.com/c/1hiSw14kplv9…

Check out our study on immune-related AEs (irAEs) to IO in patients with m+ or LA #urothelialcarcinoma pubmed.ncbi.nlm.nih.gov/37422731/ We relied on #IPD of IM210/1 from Vivli IO acts by de-inhibiting the immune system and reactions against self antigens are not uncommon.

"The main question in light of the overall survival findings ... is whether patients with mCRPC should be treated with combination therapy up front irrespective of their HRR mutation status." Linked Comment by Alberto Martini et al. thelancet.com/journals/lanon…

Happy for the publication Eur Urol Focus of our new paper from EAU Young Academics with Giuseppe Fallara and team. Grateful for the support of my collegues andrology at king’s KCH_Urology , which is growing both clinically and academically. omer onur cakir Maria Satchi Angelo Territo

Buongiorno da @oltredna 🇮🇹 - 🧵 Il nostro obiettivo è la prevenzione e la diagnosi precoce grazie alla medicina personalizzata. Contribuiamo ad un futuro nel quale la diagnosi precoce e la personalizzazione delle cure siano realtà.

hot-off-press📝antiangiogenics+immune checkpoint blockade in urothelial cancer: Sys rev and meta-analysis Mohammad Jad Moussa, MD, MSc, Iuliia Kovalenko, MD, Emanuele Crupi, E Proskuriakova, Y. Geng, Giuseppe Fallara, R. Benkhadra, Daniele Raggi, Matt Campbell MD, MS Pavlos Msaouel journals.sagepub.com/doi/10.1177/23…